Understanding how different hepatitis B vaccines affect immune responses in people living with HIV
Official title: Dissecting Hepatitis B Vaccine Adjuvant Effects on Immune Responses and the HIV Reservoir in PLWH
Funded at Johns Hopkins University · NIH-11144593 · Data updated 2026-11-12
This study is looking at how well two different hepatitis B vaccines work for people living with HIV, comparing the usual vaccine, ENGERIX-B, with a newer one, HEPLISAV-B, to see if the new vaccine offers better protection.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 25, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $822,489 |
| NIH project number | 5R01AI186730-02 |
| Project ID | NIH-11144593 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who have previously been vaccinated against hepatitis B but did not achieve protective antibody levels.
✕Less likely to help
Patients who are not living with HIV or those who have not been vaccinated against hepatitis B may not benefit from this research.
What this research studies
This research investigates the immune responses generated by two different hepatitis B vaccines in individuals living with HIV. It compares the standard vaccine, ENGERIX-B, with a newer vaccine, HEPLISAV-B, which uses a special adjuvant to enhance the immune response. By analyzing the immune signatures and responses from both vaccines, the study aims to identify why HEPLISAV-B may lead to better protection against hepatitis B in this population. The findings could help improve vaccination strategies for people living with HIV.
Why it matters
Potential benefit: If successful, this research could lead to more effective hepatitis B vaccination strategies for people living with HIV, reducing their risk of liver disease and cancer.
How similar studies have gone: Previous research has shown promising results with the HEPLISAV-B vaccine, indicating that this approach could lead to significant advancements in hepatitis B vaccination for people living with HIV.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Cox, Andrea L — Johns Hopkins University
- Study coordinator: Cox, Andrea L
Related research
Other NIH-funded projects on the same topics.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
-
HBV cure factors in people with and without HIV
This project studies how HBV-specific immune cells behave during treatment and whether people with HIV respond differently than those without HIV.
-
HBV prevention in community pharmacies: a first step in a low-resource setting
This pilot project tests whether hepatitis B screening and vaccination can be integrated into everyday community pharmacy services to reach more people.
-
Blood markers to catch early liver cancer in Hispanic people with hepatitis B
This project will see if a blood test can find liver cancer earlier in Hispanic people who have chronic hepatitis B.
-
Early blood markers to find hepatitis B–related liver cancer in Hispanics
This project will use immune-related blood markers to find liver cancer earlier in people with chronic hepatitis B, focusing on Hispanic adults.
-
HBV safety with long-acting HIV therapy for people with HIV
A study to understand how long-acting HIV meds affect hepatitis B in people living with HIV and how to best monitor and protect them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.